Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options
Background: The clinical outcomes of everolimus rechallenge in patients with pancreatic neuroendocrine neoplasms (PNENs) are unknown. This study aimed to investigate the treatment outcomes and safety of everolimus rechallenge treatment with PNENs. Methods: Clinical data of everolimus-treated patient...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/22/5669 |
| _version_ | 1797465716906000384 |
|---|---|
| author | Yusuke Kurita Noritoshi Kobayashi Kazuo Hara Nobumasa Mizuno Takamichi Kuwahara Nozomi Okuno Shin Haba Motohiko Tokuhisa Sho Hasegawa Kensuke Kubota Atsushi Nakajima Yasushi Ichikawa |
| author_facet | Yusuke Kurita Noritoshi Kobayashi Kazuo Hara Nobumasa Mizuno Takamichi Kuwahara Nozomi Okuno Shin Haba Motohiko Tokuhisa Sho Hasegawa Kensuke Kubota Atsushi Nakajima Yasushi Ichikawa |
| author_sort | Yusuke Kurita |
| collection | DOAJ |
| description | Background: The clinical outcomes of everolimus rechallenge in patients with pancreatic neuroendocrine neoplasms (PNENs) are unknown. This study aimed to investigate the treatment outcomes and safety of everolimus rechallenge treatment with PNENs. Methods: Clinical data of everolimus-treated patients with PNENs at two institutions were collected. Patients who underwent everolimus rechallenge were included in the study. We analyzed the progression-free survival (PFS) and treatment response associated with everolimus rechallenge and the adverse events. Results: Between 2008 and 2020, 117 patients received initial treatment with everolimus, of which 14 patients received everolimus rechallenge. With regard to the grade of PNENs, there were 2 cases of G1, 11 cases of G2, and 1 case of G3. The median rechallenge PFS was 5.7 months. The objective response rate was 21.4%. the disease control rate was 71.4%. The only major grade 3 or 4 adverse event was neutropenia (<i>n</i> = 1, 7.1%). No other severe adverse event was observed. Conclusion: The outcomes and safety of everolimus rechallenge were verified, and it was deemed an acceptable treatment. Everolimus rechallenge may provide a new drug therapy for patients with advanced PNENs for whom no other drug treatment option is available. |
| first_indexed | 2024-03-09T18:25:29Z |
| format | Article |
| id | doaj.art-822070c35f804736875e914d5bf5db20 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T18:25:29Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-822070c35f804736875e914d5bf5db202023-11-24T07:54:49ZengMDPI AGCancers2072-66942022-11-011422566910.3390/cancers14225669Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment OptionsYusuke Kurita0Noritoshi Kobayashi1Kazuo Hara2Nobumasa Mizuno3Takamichi Kuwahara4Nozomi Okuno5Shin Haba6Motohiko Tokuhisa7Sho Hasegawa8Kensuke Kubota9Atsushi Nakajima10Yasushi Ichikawa11Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, JapanDepartment of Oncology, Yokohama City University Hospital, Yokohama 236-0004, JapanDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Oncology, Yokohama City University Hospital, Yokohama 236-0004, JapanDepartment of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, JapanDepartment of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, JapanDepartment of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, JapanDepartment of Oncology, Yokohama City University Hospital, Yokohama 236-0004, JapanBackground: The clinical outcomes of everolimus rechallenge in patients with pancreatic neuroendocrine neoplasms (PNENs) are unknown. This study aimed to investigate the treatment outcomes and safety of everolimus rechallenge treatment with PNENs. Methods: Clinical data of everolimus-treated patients with PNENs at two institutions were collected. Patients who underwent everolimus rechallenge were included in the study. We analyzed the progression-free survival (PFS) and treatment response associated with everolimus rechallenge and the adverse events. Results: Between 2008 and 2020, 117 patients received initial treatment with everolimus, of which 14 patients received everolimus rechallenge. With regard to the grade of PNENs, there were 2 cases of G1, 11 cases of G2, and 1 case of G3. The median rechallenge PFS was 5.7 months. The objective response rate was 21.4%. the disease control rate was 71.4%. The only major grade 3 or 4 adverse event was neutropenia (<i>n</i> = 1, 7.1%). No other severe adverse event was observed. Conclusion: The outcomes and safety of everolimus rechallenge were verified, and it was deemed an acceptable treatment. Everolimus rechallenge may provide a new drug therapy for patients with advanced PNENs for whom no other drug treatment option is available.https://www.mdpi.com/2072-6694/14/22/5669pancreasneuroendocrine neoplasmseverolimus |
| spellingShingle | Yusuke Kurita Noritoshi Kobayashi Kazuo Hara Nobumasa Mizuno Takamichi Kuwahara Nozomi Okuno Shin Haba Motohiko Tokuhisa Sho Hasegawa Kensuke Kubota Atsushi Nakajima Yasushi Ichikawa Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options Cancers pancreas neuroendocrine neoplasms everolimus |
| title | Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options |
| title_full | Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options |
| title_fullStr | Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options |
| title_full_unstemmed | Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options |
| title_short | Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options |
| title_sort | clinical outcomes of everolimus rechallenge in patients with pancreatic neuroendocrine neoplasms with no other treatment options |
| topic | pancreas neuroendocrine neoplasms everolimus |
| url | https://www.mdpi.com/2072-6694/14/22/5669 |
| work_keys_str_mv | AT yusukekurita clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT noritoshikobayashi clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT kazuohara clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT nobumasamizuno clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT takamichikuwahara clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT nozomiokuno clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT shinhaba clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT motohikotokuhisa clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT shohasegawa clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT kensukekubota clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT atsushinakajima clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions AT yasushiichikawa clinicaloutcomesofeverolimusrechallengeinpatientswithpancreaticneuroendocrineneoplasmswithnoothertreatmentoptions |